罗沙司他治疗肾性贫血的效果及安全性分析

Efficacy and Safety Analysis of Rosallistat in the Treatment of Renal Anemia

目的:探讨罗沙司他治疗肾性贫血的效果及安全性。方法:选取2022年6月—2023年6月赤水市人民医院收治的肾性贫血患者72例作为研究对象,随机分为观察组及对照组,各36例。对照组给予重组人促红细胞生成素治疗,观察组给予罗沙司他治疗。比较两组治疗效果及安全性。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P=0.024)。观察组不良反应总发生率低于对照组,差异有统计学意义(P=0.021)。治疗后,两组铁蛋白水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组红细胞计数、血红蛋白、血细胞比容水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。结论:罗沙司他治疗肾性贫血的效果显著且安全性高,可改善患者贫血指标。

Objective:To investigate the efficacy and safety of Rosallistat in the treatment of renal anemia.Methods:A total of seventy-two patients with renal anemia treated in Chishui People's Hospital from June 2022 to June 2023 were selected as the study objects and randomly divided into observation group and control group,with thirty-six patients in each group.The control group was treated with recombinant human erythropoietin,and the observation group was treated with Rosallistat.The therapeutic effect and safety of the two groups were compared.Results:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P=0.024);The total incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P=0.021);After treatment,the ferritin level in both groups was higher than before treatment,and the observation group was higher than the control group,the difference was statistically significant(P<0.05);After treatment,red blood cell count,hemoglobin and hematocrit levels in the two groups were higher than before treatment,and observation group was higher than control group,the difference was statistically significant(P<0.05).Conclusion:Rosallistat is effective and safe in the treatment of renal anemia,and can improve the anemia index of patients.